At a Glance
| Allylescaline | 25B-NBOMe | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Routes | oral | insufflatedsublingual |
| Effects | 42 documented | 42 documented |
Allylescaline, a Psychedelic, and 25B-NBOMe, a Psychedelic, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. Both are classified as Psychedelics, meaning they share a common pharmacological foundation. They share 28 documented effects in common, with 14 effects unique to Allylescaline and 14 unique to 25B-NBOMe. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| Allylescaline | 25B-NBOMe | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Routes | oral | insufflatedsublingual |
| Effects | 42 documented | 42 documented |
| Interaction | Low Risk & Synergy | |
| Level | Dose |
|---|---|
| Threshold | 15 mg |
| Light | 20–30 mg |
| Common | 30–40 mg |
| Strong | 40–60 mg |
| Heavy | 60 mg |
| Level | Dose |
|---|---|
| Threshold | 25 µg |
| Light | 50–200 µg |
| Common | 200–350 µg |
| Strong | 350–500 µg |
| Level | Dose |
|---|---|
| Threshold | 50 µg |
| Light | 100–300 µg |
| Common | 300–500 µg |
| Strong | 500–700 µg |
Cross-tolerance exists; effects compound
No dangerous interactions recorded.
No dangerous interactions recorded.